Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Adavosertib

(AZD1775)

Phase 2Small molecule

AZD1775 is an experimental cancer drug being tested to treat various types of cancer by targeting a protein that helps cancer cells survive and divide.[1] Adavosertib is currently being investigated across 13 indications[3], with its most advanced program in Phase 2.[1]

Adavosertib is one of 319 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

13

Indications

23

Total Trials

5

Active Trials

318

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Ovarian CarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Uterine CarcinosarcomaActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Bladder CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Pediatric CancerRecruiting

Lung CancerPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Ovarian CarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Uterine CarcinosarcomaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Bladder CancerPhase 1

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Pediatric CancerPreclinical

Recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adavosertib

Trodelvy

Tykerb

Tecentriq

Halaven

Adriamycin

GGynecologic Oncology Group

Avastin

BBio-Thera Solutions

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Prolia

Gemzar

GGynecologic Oncology Group

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8

NCT04460937

Phase 2Active, not recruiting

Advanced Lymphoma

NCT02465060

Q3 2027

Phase 2Active, not recruiting

Uterine Carcinosarcoma

NCT03668340

Q1 2031

PreclinicalRecruiting

Pediatric Cancer

NCT02813135

Clinical

Trials by Indication[1]

Lung Cancer4 trials

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02087176·48 enrolled

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02513563·42 enrolled

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02087241·22 enrolled

Show 1 more trial

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02937818·72 enrolled

Small Cell Lung Cancer2 trials

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Completed·SSamsung Medical Center·Phase 2·NCT02593019·24 enrolled

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Terminated·SSamsung Medical Center·Phase 2·NCT02688907·7 enrolled

Gastric Adenocarcinoma1 trial

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Completed·SSamsung Medical Center·Phase 2·NCT02448329·26 enrolled

Metastatic Colorectal Cancer1 trial

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Completed·NNYU Langone Health·Phase 1·NCT02906059·7 enrolled

Pancreatic Cancer1 trial

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02194829·8 enrolled

14 more indications

Uterine Carcinosarcoma1 trial

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Active, not recruiting·—·Phase 2·NCT03668340·49 enrolled

Advanced or Metastatic Solid Tumour1 trial

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02610075·62 enrolled

Advanced Solid Tumours1 trial

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02617277·56 enrolled

Head and Neck Cancer1 trial

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

Completed·UUniversity of Birmingham·Phase 1·NCT03028766·9 enrolled

Bladder Cancer1 trial

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT02546661·117 enrolled

Cisplatin1 trial

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT02585973·12 enrolled

Breast Cancer1 trial

CISPLATIN + AZD-1775 In Breast Cancer

Completed·—·Phase 2·NCT03012477·34 enrolled

Refractory Solid Tumors1 trial

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02511795·128 enrolled

Solid Tumours1 trial

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02341456·19 enrolled

Recurrent1 trial

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Completed·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 1·NCT02207010·20 enrolled

Pediatric Cancer1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Preclinical·NCT02813135·472 enrolled

Advanced Lymphoma1 trial

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

Clinical Stage III Esophageal Adenocarcinoma AJCC v81 trial

A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04460937·4 enrolled

Unspecified1 trial

OLAParib COmbinations

Terminated·JJoseph Paul Eder·Phase 2·NCT02576444·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for AZD1775. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD1775 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD1775. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Related News